يحاول ذهب - حر

The Zika Comeback: One Vaccine, One Hope

BioSpectrum Asia Nov 2025

|

BioSpectrum Asia

Asia, the epicenter of flaviviruses like Japanese encephalitis (JE), dengue, and Zika, faces both a critical need and a strategic opportunity to lead vaccine development. Phylogenetic evidence shows that the Zika strain behind the Americas outbreak originated in Southeast Asia. With global pipelines favouring high-income markets, regional biotech can drive preventive solutions, scale production, and avert outbreaks as Zika quietly resurfaces across Southeast Asia.

The Zika Comeback: One Vaccine, One Hope

Nearly a decade after the world's attention was gripped by the Zika virus outbreak in Brazil, the disease is quietly making a comeback in Asia. In recent years, clusters of infections have been reported in Singapore, imported cases traced back to Bali have been identified in South Korea, and other sporadic outbreaks have been recorded across Southeast Asia.

In 2023, 758 Zika cases were reported in Thailand, up from 190 in 2022, reflecting a surge of over 300 per cent. Among them were 33 women and 15 newborns presenting with Zika and congenital Zika syndrome respectively. Singapore reported 15 cases of Zika in the same year. In 2025, the Singapore's National Environment Agency reported two cases in June, while Thailand's Ministry of Public Health issued a warning in July about an increase in Zika cases across three Thai provinces including Bangkok

While the numbers remain relatively small compared to dengue or malaria, the reappearance of Zika is concerning. It underscores how climate change, rising temperatures, and frequent flooding are enabling Aedes mosquitoes to thrive, increasing the risk of mosquito-borne infections in the region.

The urgency: Asia's resurgent threat

For many, Zika is associated with the outbreak around the 2016 Olympic Games in Brazil and feels like something that happened long ago and far away. But what most people don't know is that there is phylogenetic evidence that the strain of Zika virus that caused the serious outbreak of the disease in Brazil and the Americas had its origin in Southeast Asia.

Although first isolated in a sentinel monkey in the Zika Forest in Uganda in 1947, serological studies published in the 1950s and 1960s showed that there was already a wide geographic footprint for Zika virus in Southeast Asia, ranging from Pakistan to the Philippines; which is why public health experts warn that Asia cannot afford to be complacent.

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Listen

Translate

Share

-
+

Change font size